Kymera TherapeuticsKYMR could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results ...

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

A diagnosis of T-cell lymphoma after using Dupixent raises serious questions for patients and families. Many want clear ...

A few months after Sanofi and Regeneron’s Dupixent scored a new indication as the first and only medicine to treat eosinophilic esophagitis (EoE) in patients 12 and older, new late-stage trial data ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Dupixent is a blockbuster immunology drug that just keeps delivering for Sanofi and Regeneron, so it’s no surprise that the “franchise in a therapy” has got a new set of ads. Sanofi and Regeneron, ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

TRENTON, N.J. --U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema. The Food and Drug Administration on Tuesday approved Dupixent ...